Skip to main content
Erschienen in: Intensive Care Medicine 4/2019

25.03.2019 | Editorial

Direct oral anticoagulants for venous thromboembolism prophylaxis in critically ill patients: where do we go from here?

verfasst von: Laurent Bertoletti, Martin Murgier, Henry T. Stelfox

Erschienen in: Intensive Care Medicine | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Excerpt

Venous thromboembolism (VTE) is an important problem and a particular challenge for critically ill patients. First, admission to an intensive care unit (ICU) is as a strong independent risk factor for provoked VTE [1] with an incidence of approximately 9% [2]. Second, establishing a diagnosis of VTE in critically ill patients is more likely to be delayed or missed than for other patient populations because of comorbid illnesses (e.g., heart failure) and therapies (e.g., sedation) that mask symptoms and signs [1]. Third, critically ill patients diagnosed with VTE experience more anticoagulant therapy-related complications because of increased bleeding risk [1, 3]. Together these three challenges make effective VTE prophylaxis particularly important for critically ill patients. Epidemiological data suggest that earlier initiation of thromboprophylaxis is associated with reduced incidence of VTE and increased survival [4]. Randomized controlled trials (RCTs) have established the efficacy of heparins in the prevention of VTE in ICU patients [5, 6]. The question remains whether new approaches to prophylaxis can further decrease the risk of VTE without increasing complications. …
Literatur
1.
Zurück zum Zitat Minet C, Potton L, Bonadona A et al (2015) Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care 19:287CrossRefPubMedPubMedCentral Minet C, Potton L, Bonadona A et al (2015) Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care 19:287CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Alhazzani W, Lim W, Jaeschke RZ et al (2013) Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med 41:2088–2098CrossRefPubMed Alhazzani W, Lim W, Jaeschke RZ et al (2013) Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med 41:2088–2098CrossRefPubMed
3.
Zurück zum Zitat Decousus H, Tapson VF, Bergmann J-F et al (2011) Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139:69–79CrossRefPubMed Decousus H, Tapson VF, Bergmann J-F et al (2011) Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139:69–79CrossRefPubMed
4.
Zurück zum Zitat Ho KM, Chavan S, Pilcher D (2011) Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 140:1436–1446CrossRefPubMed Ho KM, Chavan S, Pilcher D (2011) Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 140:1436–1446CrossRefPubMed
5.
Zurück zum Zitat Duranteau J, Taccone FS, Verhamme P, Ageno W (2018) European guidelines on perioperative venous thromboembolism prophylaxis: intensive care. Eur J Anaesthesiol 35:142–146PubMed Duranteau J, Taccone FS, Verhamme P, Ageno W (2018) European guidelines on perioperative venous thromboembolism prophylaxis: intensive care. Eur J Anaesthesiol 35:142–146PubMed
6.
Zurück zum Zitat Schünemann HJ, Cushman M, Burnett AE et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2:3198–3225CrossRefPubMedPubMedCentral Schünemann HJ, Cushman M, Burnett AE et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2:3198–3225CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Bertoletti L, Ollier E, Duvillard C et al (2017) Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol Res 118:33–42CrossRefPubMed Bertoletti L, Ollier E, Duvillard C et al (2017) Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol Res 118:33–42CrossRefPubMed
8.
Zurück zum Zitat Cohen AT, Spiro TE, Büller HR et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513–523CrossRefPubMed Cohen AT, Spiro TE, Büller HR et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513–523CrossRefPubMed
9.
Zurück zum Zitat Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2177CrossRefPubMed Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2177CrossRefPubMed
10.
Zurück zum Zitat Cohen AT, Harrington RA, Goldhaber SZ et al (2016) Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 375:534–544CrossRefPubMed Cohen AT, Harrington RA, Goldhaber SZ et al (2016) Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 375:534–544CrossRefPubMed
11.
12.
13.
Zurück zum Zitat Niven DJ, Rubenfeld GD, Kramer AA, Stelfox HT (2015) Effect of published scientific evidence on glycemic control in adult intensive care units. JAMA Intern Med 175:801–809CrossRefPubMed Niven DJ, Rubenfeld GD, Kramer AA, Stelfox HT (2015) Effect of published scientific evidence on glycemic control in adult intensive care units. JAMA Intern Med 175:801–809CrossRefPubMed
14.
Zurück zum Zitat Fowler RA, Mittmann N, Geerts WH et al (2014) Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. Trials 15:502CrossRefPubMedPubMedCentral Fowler RA, Mittmann N, Geerts WH et al (2014) Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. Trials 15:502CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Stelfox HT, Brundin-Mather R, Soo A et al (2019) A multicentre controlled pre-post trial of an implementation science intervention to improve venous thromboembolism prophylaxis in critically ill patients. Intensive Care Med 45:211–222CrossRefPubMed Stelfox HT, Brundin-Mather R, Soo A et al (2019) A multicentre controlled pre-post trial of an implementation science intervention to improve venous thromboembolism prophylaxis in critically ill patients. Intensive Care Med 45:211–222CrossRefPubMed
Metadaten
Titel
Direct oral anticoagulants for venous thromboembolism prophylaxis in critically ill patients: where do we go from here?
verfasst von
Laurent Bertoletti
Martin Murgier
Henry T. Stelfox
Publikationsdatum
25.03.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 4/2019
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-019-05605-1

Weitere Artikel der Ausgabe 4/2019

Intensive Care Medicine 4/2019 Zur Ausgabe

Imaging in Intensive Care Medicine

Post-intubation tracheal laceration

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.